OncRef

Clinical Trial: NCT01903993

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2019-10-02

Study Overview

Brief Summary

This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure. Participants will be randomized to receive either Atezolizumab 1200 milligram (mg) intravenously every 3 weeks or docetaxel 75 milligram per meter square (mg/m^2) intravenously every 3 weeks. Treatment with Atezolizumab may be continued as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Official Title

A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Docetaxel
  • Drug: Atezolizumab

Other Study ID Numbers

  • GO28753
  • 2013-001142-34

Start Date (Actual)

2013-08-06

Primary Completion Date (Actual)

2015-11-19

Study Completion Date (Actual)

2018-09-06

Enrollment (Actual)

287

Study Type

Interventional

Phase

Phase 2